Transpharmation Logo
  • Contact Us

Models & Assays

Drug Self-administration

Self-administration is the gold-standard for assessing reinforcement. Self-administration studies assess voluntary consumption of a compound. Safety studies examine the ability of a novel compound to maintain operant responding for drug delivery compared to vehicle and a drug of abuse from the same class or therapeutic category. Efficacy studies evaluate whether a novel compound can reduce reinforcement of a known drug of abuse. Transpharmation offers oral and intravenous self-administration using a variety of schedules of reinforcement.

Aspects of self-administration: Acquisition, Dose-response, Progressive ratio (motivation), Reinstatement (model of relapse) and Drug pretreatment.

Self-administration: Dose Response

Data presented: Male Sprague-Dawley rats modulate their behaviour and intake depending on the intravenous dose per infusion they receive.

Self-administration: Drug Pretreatment

Data presented: The 5-HT2C agonist Lorcaserin dose-dependently reduces responding for, and intake of, IV cocaine on a fixed ratio 2 and progressive ratio schedule of reinforcement in male Sprague-Dawley rats.

Self-administration: Reinstatement (model of relapse)

Data presented: Following extinction (Ext) of responding for IV nicotine, reinstatement of drug-seeking was assessed in male and female Sprague-Dawley rats. During cue-induced reinstatement sessions (Cue), rats responded for only activation of a cue-light previously associated with nicotine delivery. During drug and cue reinstatement sessions (Nic+Cue), rats received an injection of nicotine (0.15mg/kg, SC) immediately prior to a session where rats responded for activation of the nicotine-paired cue-light.

Company

  • Our Team
  • Publications
  • News
  • Careers
  • Animal Welfare
  • Privacy Policy
  • Accessibility Policy
  • Cookies Policy

Services

  • Abuse Liability / Substance Use Disorders
  • Alzheimer's Disease
  • Bioanalytical Studies
  • CNS Drug Disposition
  • Cognitive Assessment
  • Depression/Anxiety
  • Dermatology
  • EEG
  • Epilepsy
  • Essential Tremor
  • Imaging
  • Inflammatory Pain
  • Inflammation
  • Medical Cannabis
  • Metabolic Disorders
  • Migraine
  • Molecular Biomarkers
  • Multiple Sclerosis
  • Neuropathic Pain
  • Operant Platform
  • Osteoarthritis
  • Parkinson's Disease
  • PK/PD Studies
  • PK-Bridge
  • Psychedelics
  • PXB Mouse Studies
  • Safety Studies
  • Schizophrenia
  • Veterinary Research
North America
1-548-538-2371
Europe
+44 (0)130 440 3165
Contact us

© 2024 Transpharmation™. All Rights Reserved.
Sitemap
LinkedIn account
Youtube account